Synapticure
ActiveWe deliver personalized medicine for neurodegenerative patients
This company has previously operated under “SynaptiCure Inc.”, “SynaptiCure”. A rename frequently marks a pivot in positioning or product — useful raw material for variant ideas.
About
Personalized virtual clinical care is finally here for neurodegenerative diseases like Alzheimer's and related Dementias (Cognitive), Parkinson's and Huntington's (Movement), and ALS (Motor neuron). We provide a novel approach to care in these diseases, centering a patient and caregiver around a coordinator who quarterbacks patients through our full Multi-Disciplinary Care Resources to local aid, PT/OT and home health support. When you leave our clinic, it's not with a handful of paper referrals, but with our coordinators helping you book and find the best physicians, DME, trials, and even cheapest prescriptions. We are devoted to helping patients, from guidance on care and insurance to providing the full spectrum of investigational and clinical testing to improve outcomes. Synapticure was built by leading patient and caregiver advocates alongside leading clinicians, biotech executives and telemedicine executives to bring the neurodegenerative disease care and treatment experience into the 21st century, and is backed by the leading Venture funds and investors in the remote health and life sciences space.
Founders · 3
Founder / Founding CEO, SynaptiCure Inc. Eternal optimist. Recovering Bain consultant and avid baseball fan.
Brian Wallach is an attorney and ALS patient. In the aftermath of his diagnosis in November 2017, he and his wife founded I AM ALS, a patient-led, patient-centric movement to lead the fight for a cure to the disease. Wallach is also an associate at the law firm Skadden, Arps, Slate, Meagher & Flom LLP. From 2014 to 2018, he served as an assistant United States attorney in the Northern District of Illinois. From 2011 to 2013, he was senior vetting counsel in the Obama White House.
Martina is the director of research and development at Synapticure and she focuses on creating iPSC derived in vitro models to study neurodegenerative disorders. Martina received an undergraduate degree in biotechnology and a Master's degree in pharmaceutical biotechnology from the University of Rome "La Sapienza" (Italy), she then earned a PhD in clinical neuroscience from King's College London (UK) and deepened her knowledge of iPSC derived modelling in her postdoc at UCSF (US)
Related startups
Bringing non-invasive brain stimulation from the hospital to the home
Curative genetic medicines for kidney diseases
